Kornimate/medical-research-clean huggingface dataset:
comparing liquid versus solid forms of sugars and whey protein

Conditions: Diabetes; Obesity

Summary: to compare the effect of eating solid vs. drinking liquid forms of gelatin, sucrose and its component mixtures and whey protein on subjective appetite and food intake in young men.

three randomized cross-over design experiments were used to compare the effect of solid and liquid forms of gelatin (6 g) in experiment 1, sucrose (75 g) and a mixture of 50% glucose/ 50% fructose (g50:f50) in experiment 2, and acid and sweet whey protein (50 g) in experiment 3 on healthy normal weight males . the controls were water (experiment 1 and 3) and calorie-free sweetened water with gelatin (sweet gelatin, experiment 1) or without gelatin (sweet control, experiment 2). subjective average appetite was measured by visual analogue scales frequently over 1 h and ad libitum food intake was measured 1 h after the treatment consumptions.

Eligibility criteria:
inclusion criteria: * healthy lean males with bmi between 18- 24.9 kg/m2 and an age range of 19 to 28 years were recruited for the three experiments. exclusion criteria: * diabetics (fasting blood glucose ≥ 7.0 mmol/l), smokers, breakfast skippers or dieters were excluded from the experiments. individuals under medications or with a history of liver or kidney disease and major medical or surgical event within the last six months were excluded.
olmesartan medoxomil in atherosclerosis

Conditions: Essential Hypertension; Atherosclerotic Cardiovascular Disease

Summary: this is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. the efficacy of olmesartan medoxomil on atherosclerosis is measured.


Eligibility criteria:
inclusion criteria: * mean sitting sbp and dbp prior to randomization of 140-180/90-105 mmhg * increased cardiovascular risk, e.g.: a) documented or clinical signs of peripheral atherosclerotic disease stage iia or lower; b) diabetes mellitus type 2; c) left ventricular hypertrophy on echo; d) current smoking; e) old myocardial infarction, stroke or tia * intima-media thickness of the common carotid artery greater than or equal to 0.8 and less than or equal to 1.6 mm (measured ultrasonographically) or the plaque volume of the carotid bulb greater than or equal to 4 μl and less than or equal to 500 μl exclusion criteria: * body mass index \> 30 * any type of known secondary hypertension * electrocardiographic evidence of 2nd or 3rd degree atrioventricular block, atrial fibrillation, cardiac arrhythmia requiring therapy or bradycardia at rest (\< 50/min) * obstructive pulmonary disease * claudicatio intermittens * history or clinical evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial * hypersensitivity or contraindication to arbs, beta-blockers, hctz or any cross allergy * pre-treatment with arbs or ace inhibitors within 6 months prior to screening * treatment with disallowed medication * pregnant or breastfeeding females or females of childbearing potential without adequate contraception * history of alcohol and/or drug abuse
exploring virtual reality as an intervention for food selectivity: a clinical trial

Conditions: Autism; Autism Spectrum Disorder

Summary: food selectivity is a common challenge among children with autism spectrum disorder (asd), with significant impacts on their nutrition and well-being. the main purpose of this study is to promote children's active participation in mealtime routines and encourage experimentation with new foods through an approach that emphasizes joy and serenity during mealtimes. the study will involve children with asd between the ages of 4 and 10 years, of both sexes. food selectivity will be assessed through interviews with parents and the use of specially created cards. the protocol will include 45-minute sessions, twice a week, for a total of 48 sessions. the children will wear an oculus headset and be exposed to the foods through this virtual reality tool, enhancing their engagement and willingness to try new foods in a fun and immersive way.


Eligibility criteria:
inclusion criteria: * food selectivity upon parental referral * child with diagnosis of autism exclusion criteria: * presence of other medical disorders

Keywords: autism children food selectivity virtual reality
effects of remote ischemic preconditioning and postconditioning on lung injury during cardiopulmonary bypass

Conditions: Acute Lung Injury

Summary: remote ischemic preconditioning(ripc) and remote ischemic postconditioning(ripoc) seems to have a protective effect during ischemic period. using cardiopulmonary bypass(cpb) during open heart surgery reduces pulmonary blood flow and may cause ischemic damage to lung tissue. the investigators anticipate that ripc and ripoc may reduce lung injury after cpb.

cardiopulmonary bypass(cpb) can cause lung function deterioration through various mechanisms. lung parenchymal tissue ischemia resulted by pulmonary atelectasis and decreased bronchial circulation during cpb is one of the reasons. there were few studies reported that ripc and ripoccan benefit lung function of children or infant after cpb, but studies about adults are still lacking. purpose: the purpose of this study is to evaluate effect of ripc and ripoc on the lung function after cpb. methods: patients will randomly allocated either in study group or control group. study group will receive ripc and ripoc maneuver before and after cpb. control group will have same automated cuff around their arm but it will not activated. care givers will be blinded whether the automated cuff is on or not. we will compare pulmonary parameters (pao2/fio2, dynamic and static compliances, intrapulmonary shunts, etc.) between study group and control group, and check levels of plasma cytokines(il-4, il-8, il-10, tnf-alpha) till 24hr after the operation.

Eligibility criteria:
inclusion criteria: * those who aged 18-80 years old and planned to undergo elective open heart surgery using cardiopulmonary bypass exclusion criteria: * emergent operation * preoperative use of inotropics or mechanical assist device, * left ventricular ejection fraction less than 30%, * severe liver, renal disease, * recent myocardial infarction (within 7 days), * recent systemic infection or sepsis (within 7 days) * peripheral vascular disease affecting upper limbs * amputation of the upper limbs * major combined operation such as aortic surgery or carotid endarterectomy * descending thoracic aortic surgery * rare surgeries; cardiac transplantation, correction of complicated congenital anomalies, pulmonary thromboembolectomy, etc * significantly decreased pulmonary function before the planned surgery (e.g. using ventilator, oxygen therapy, tachypnea, orthopnea, active lung lesion on chest x-ray, fev1/fvc less than 50% of predicted level, pao2 less than 80 mmhg) * intracardiac shunt * severe pulmonary artery hypertension * systemic or local steroid therapy

Keywords: ripc lung protection ischemic reperfusion injury cardiopulmonary bypass
high dose vit d musculoskeletal symptoms & bone density in anastrozole-treated breast cancer with marginal vit d status

Conditions: Breast Neoplasms

Summary: the purpose of this study is to determine whether vitamin d supplementation reduces the symptoms of muscle stiffness and joint tenderness that some patients may develop after starting therapy with anastrozole for breast cancer.

this is a pilot, double-blind, randomized, placebo-controlled study with the following aims: * to compare the effects of high dose vitamin d versus standard dose vitamin d on musculoskeletal pain in breast cancer patients receiving anastrozole when vitamin d levels are in the insufficient but not deficient range (10 to 29 ng/ml). * to evaluate the prevalence of vitamin d insufficiency/deficiency in post-menopausal women with a history of breast cancer who are treated with anastrozole and have musculoskeletal symptoms versus those who are asymptomatic. * to establish correlations between levels of vitamin d, the levels of pth, the degree of bone loss and the severity of musculoskeletal symptoms. * to evaluate the effect of standard dose versus high dose vitamin d replacement on bone density in post-menopausal women with a history of breast cancer who are treated with anastrozole and have musculoskeletal symptoms.

Eligibility criteria:
inclusion criteria * women with a diagnosis of hormone receptor positive invasive breast cancer (stage i-iiib) or ductal carcinoma in situ (dcis) * postmenopausal status * completed at least 8 weeks of anastrozole as adjuvant therapy prior to study entry * completed systemic chemotherapy and radiation treatments when indicated * serum calcium ≤ 10.3 mg/dl * patients with marginal 25 oh vitamin d level (between 10 and 29 ng/ml) will be in the randomized group or low 25 oh vitamin d level (less than 10 ng/ml) will be in observational group * 24-hour urine calcium excretion ≤ 250 mg/g (calculated by dividing 24 hour calcium by 24 hour creatinine) * a history of generalized musculoskeletal pain with or without localized regions or discomfort that has developed or worsened since starting adjuvant aromatase inhibitor therapy exclusion criteria * known metastatic disease * history of kidney stones * history of active primary hyperparathyroidism * history of paget's disease of the bone * history of severe arthritis, rheumatoid arthritis, or severe neuropathy * normal 25 oh vitamin d level (≥ 30 ng/ml) * medical or psychiatric condition which may preclude protocol compliance
intra-operative dural brachytherapy with yttrium-90 plaque applicators

Conditions: Spinal Neoplasms

Summary: the purpose of this clinical trial is to determine the feasibility of the y-90 plaque applicator. the y-90 plaque application is designed to deliver high doses of radiation to tumors in the spine that involve dura (the tough outer layer of the spinal cord). tumors in the spine need a high dose of radiation to kill cancer cells. the nearby spinal cord is a sensitive area which does not safely tolerate high doses of radiation. the y-90 plaque applicator is a special technique used to deliver the radiation dose to the tumor cells and avoid the spinal cord.

* the surgeon will remove the participants tumor from the outer layer of the spinal cord (dura). the y-90 applicator and a "dummy" applicator will be brought to the surgery table in a protected container. a "dummy" applicator is the same size and shape as the y-90 plaque applicator but does not contain radioactive plaque. the "dummy" applicator will be placed on the participants dura to make sure it fits properly, then it will be removed. the working y-90 applicator will be placed on the dura for 10-17 1/2 minutes and then be removed. * external beam irradiation is a type of high-energy radiation used to kill cancer cells and shrink tumors. this radiation will be given to the participant only if they have not had it prior to the study. * after the treatment, participants will be asked to return for a follow-up visit 6 weeks, 3 months, every 6 months thereafter for 4 years, then annually to year 10. at these visits, they will have the following: physical examination; recent medical history; mri or ct scan (twice each year) and; chest x-ray or chest ct (twice each year).

Eligibility criteria:
inclusion criteria: * pathological diagnosis of malignant tumor involving spine with extraosseous extension or arising in paraspinal soft tissues with tumor involving or abutting the dura. patients with a limited metastatic disease and tumor involving the spine or paraspinal soft tissues and who are judged to benefit from surgery will also be eligible. * lesion may be primary or recurrent after prior surgery * no clinical, radiographic or other evidence of distant metastatic tumor * fit for receiving the planned radiation dose to the affected site. no known genetic disease or medical condition associated with an abnormal radiation sensitivity. * 18 years of age or older * kps of 70 or greater (excluding consideration of poor function due to the local growth or systemic metabolic effects of the tumor exclusion criteria: * disease/conditions characterized by high radiation sensitivity * pregnancy * evidence of cord/cauda malfunction for causes other than effect os local tumor growth or due to metabolic effects of tumor

Keywords: y-90 plaque applicator dural brachytherapy
potential role of gastric lavage by paraffin oil in acute aluminum phosphide poisoning

Conditions: Toxicity, Drug

Summary: potential role of gastric lavage by paraffin oil in acute aluminum phosphide poisoning.

the study aims to investigate the potential role of gastric lavage by paraffin oil in acute aluminum phosphide poisoning: a randomized controlled clinical trial

Eligibility criteria:
inclusion criteria: * • patients with symptomatic acute aluminum phosphide poisoning exclusion criteria: * • pregnant and lactating women * asymptomatic patients with history of acute aluminum phosphide exposure. * patients with ingestion or exposure to other substances in addition to aluminum phosphide. * patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure). * patients with previous medical intervention (had gastric lavage in any medical center before admission). * patients with disturbed consciousness level * patients with post cardiac arrest cases
study of m200 (volociximab) in patients with metastatic renal cell carcinoma (rcc)

Conditions: Renal Cell Carcinoma; Metastases

Summary: this clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.


Eligibility criteria:
inclusion criteria * males and females of at least 18 years of age with metastatic rcc of predominantly clear cell histology who have received 0 to 2 prior treatment regimens for metastatic disease. * measurable disease according to response criteria for solid tumors. * negative pregnancy test (women of childbearing potential only). * pretreatment laboratory levels that meet specific criteria. * signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations * patients must have failed at least one approved or investigational tyrosine kinase inhibitor (tki). exclusion criteria * any of the following histologies of rcc: papillary, chromophobe, collecting duct, or unclassified. * known sensitivity to murine proteins or chimeric antibodies or other components of the product. * use of any investigational drug within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer). * systemic chemotherapy, immunotherapy, radiation therapy, or monoclonal antibody therapy within 4 weeks of m200 administration. * documented central nervous system (cns) tumor or cns metastasis. * history of thromboembolic events and bleeding disorders within the past year. * medical conditions that may be exacerbated by bleeding.

Keywords: kidney renal cancer carcinoma cell metastatic metastatic renal cell carcinoma rcc
clinical implications of dna analysis on adpkd

Conditions: Autosomal Dominant Polycystic Kidney Disease

Summary: autosomal dominant polycystic kidney disease (adpkd) is an inherited disease. we plan dna analysis using the next generation sequencer (ngs) and examine the relationship between mutational types and clinical phenotypes. the accuracy of dna analysis with ngs is tested by sanger's method. the kidney and life survival curves will be compared between pkd1, pkd2 and non-adpkd family members.

80 unrelated patients with adpkd attending to the kyorin university hospital whose clinical data are compiled. dna analysis is performed at otsuka pharmaceutical laboratory. clinical data include total kidney volume (tkv), tkv slope, egfr, egfr slope and other clinically relevant data.

Eligibility criteria:
inclusion criteria: * the unrelated patients with adpkd. exclusion criteria: * the patients whose clinical data are not compiled.

Keywords: autosomal dominant polycystic kidney disease pkd 1 gene pkd 2 gene truncational mutation hypomorphic mutation
leptin levels in papillary thyroid cancer

Conditions: Thyroid Cancer, Papillary; Leptin Levels

Summary: the purpose of this study is to evaluate leptin levels in females, in the setting of papillary thyroid cancer, benign thyroid nodules, and in normal females without thyroid disease.

there will be three groups in this study, but 2 of the groups are part of another study so will only recruit normal controls.

Eligibility criteria:
inclusion criteria: * female * age\>/- 19 * not currently pregnant or lactating * normal thyroid gland by history exclusion criteria: * male gender * pregnancy * lactation * age below 19 * abnormal thyroid gland by history * abnormal thyroid gland by structure using ultrasound * abnormal thyroid gland by function using tsh, free t4
predictive study on acute radiation induced oral mucositis in nasopharyngeal carcinoma patients

Conditions: Nasopharyngeal Carcinoma by AJCC V8 Stage; Radiation Induced Mucositis

Summary: exploring effective risk prediction models for severe radiation-induced oral mucositis (riom/rtom), providing a research basis for mitigating oral radiation toxicity, and effectively improving the sensitivity of dentists in predicting the risk of severe riom in locally advanced nasopharyngeal carcinoma patients.based on precise radiotherapy, it is proposed to extract oar using the contour of local oral areas. explore more accurate riom dose-response relationships.exploring a new type of fusion classifier, by complementing the information between each base classifier, helps to maximize the utilization of the information contained in different factors to build a more objective, reliable, and efficient multi criteria decision-making based risk prediction model for severe riom. it use predictive models to identify key risk factors for severe riom and further validate the effectiveness of this risk factor in reducing the risk of severe riom on risk factors for severe riom identified by the predictive mode.

this study investigates the prediction and management of radiation-induced oral mucositis (riom/rtom) in patients with locally advanced nasopharyngeal carcinoma undergoing radiotherapy. riom is a significant concern due to its impact on the quality of life for patients and its potential to disrupt radiotherapy courses, affecting local tumor control rates. we systematically analyzed multifaceted data, including dosimetric parameters, clinical factors, and oral variables, to develop a predictive model for severe riom. the effectiveness of key risk factors in mitigating the risk of severe riom was further validated to predict and potentially prevent severe riom.

Eligibility criteria:
inclusion criteria: * confirmed as nasopharyngeal carcinoma through pathological tissue biopsy, ajcc 8th edition bed staging is i-iva stage, with no distant metastasis * first time receiving radical radiation therapy and receiving rtom observation and treatment throughout the entire process in the department of stomatology * complete information on anti-tumor treatment materials * no oral mucosal diseases that have not been effectively controlled in the past or still require long-term medication treatment * other diseases that do not affect the treatment of nasopharyngeal carcinoma exclusion criteria: * failure to complete radiotherapy, or material release time delayed by more than two weeks compared to plan * there are other diseases that affect the examination and treatment of oral mucosal inflammation, such as restricted mouth opening, schegren's syndrome, etc * expected survival time less than 6 months * cases where patients withdraw from clinical trials at any time and for any reason
undiagnosed hepatitis c infection in an urban hospital

Conditions: Hepatitis C

Summary: the centers for disease control and prevention estimates that there are approximately 3.2 million people in the united states infected with hepatitis c and a significant percentage of these patients are unaware of their diagnosis. this study will attempt to determine the point prevalence of undiagnosed hepatitis c infection in an urban hospital population. all patients admitted to the hospital on two separate days will have hepatitis c testing done on leftover serum and plasma that was collected as part of routine inpatient lab work. our primary goal is to determine the number of undiagnosed hepatitis c infected patients in our hospitalized population. we will also compare these rates to specific demographic characteristics, such as age, race, gender, zip code and type of insurance to see if any associations exist between these demographics and undiagnosed hepatitis c infection.

de-identified study of hepatitis c infection point prevalence in the inpatient setting of an inner city hospital.

Eligibility criteria:
inclusion criteria: * patient admitted to temple university hospital on either of the study dates exclusion criteria: * patients admitted on both study dates will only be counted once

Keywords: hepatitis c
characterization of 24 hour spirometry profiles of inhaled bi 1744 cl and inhaled foradil in patients with chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the study is intended to characterize the lung function profile of bi1744 in copd patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. each patient will receive all four treatments.


Eligibility criteria:
inclusion criteria: * patients willing to participate with confirmed diagnosis of copd * 40 years of age or older * having a 10 pack year smoking history * able to perform serial pulmonary function tests * able to use both a dpi and respimat device exclusion criteria: * significant other disease * clinically relevant abnormal hematology, chemistry, or urinalysis * history of asthma * diagnosis of thyrotoxicosis * paroxysmal tachycardia related to beta agonists * history of mi within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year * active tuberculosis, cystic fibrosis, clinically evident bronchiectasis * significant alcohol or drug use * pulmonary resection * taking oral beta adrenergics * taking unstable oral steroids * daytime oxygen * enrolled in rehabilitation program * enrolled in another study or taking investigational products * pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control * those who are not willing to comply with pulmonary medication washouts
prehabilitation to improve functional and clinical outcomes in patients with aortic stenosis

Conditions: Aortic Stenosis

Summary: transcatheter aortic valve replacement (tavr) is a treatment alternative among high-risk elderly with aortic stenosis, however, mortality remains high. fifty percent of patients undergoing tavr exhibit frailty, a syndrome associated with poor survival. it is unknown whether interventions to improve frailty before tavr (prehabilitation) will improve outcomes after tavr. this study plans to evaluate whether simple cardiac exercise interventions to improve physical performance before tavr improves outcomes after tavr.


Eligibility criteria:
inclusion criteria: * eligibility for tavr * sppb\<9 * able to exercise * able to come for follow-up visits * able to give informed consent exclusion criteria: * new york heart association (nyha) class iii/iv congestive heart failure (chf) * presyncope or syncope as presentation * acute coronary syndrome * unable to exercise * dementia * sustained ventricular arrhythmia * stroke with neurological deficit * advanced parkinson's * participated in an exercise program

Keywords: frailty